NATURAL HISTORY AND TREATMENT OF CHRONIC NON-A, NON-B HEPATITIS

慢性非甲非乙型（NANB）肝炎患者有充分的记录， 正在进行评估，以确定这种常见的长期自然历史， 慢性肝病的症状这些患者的队列可用于 评估这种疾病的实验性疗法。一个有前途的， 随机、安慰剂对照、双盲试验，为期6个月， 在慢性非乙型肝炎患者中， 完成41例患者已完成前6个月（设盲） 研究的阶段。干扰素组21例，安慰剂组20例。是说 血清转氨酶活性和肝组织学改善 在干扰素治疗的患者中显著，但在安慰剂接受者中不显著。 18名最初接受安慰剂的患者被交叉至 接受干扰素治疗12个月。他们也有类似的反应， 治疗6个月的患者，尽管他们的长期反应率可能 再高点。

Patients with well-documented chronic non-A, non-B (NANB) hepatitis are being evaluated to determine the long-term natural history of this common form of chronic liver disease. A cohort of such patients are available to evaluate experimental therapies for this disease. A prospective, randomized, placebo-controlled, double-blind trial of a six month course of human alpha interferon in patients with chronic NANB hepatitis has been completed. Forty-one patients have completed the first 6 month (blinded) phase of the study. Twenty one received interferon and 20 placebo. Mean serum aminotransferase activities and liver histology improved significantly in interferon-treated patients but not in placebo recipients. Eighteen patients who initially received placebo were crossed over to receive interferon for 12 months. They have had a similar response to the patients treated for 6 months, although their long-term response rate may be higher.